Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

• Published in: Viruses Vol. 14; no. 4; p. 670
• Main Authors: Shinada, Kanako, Sato, Takashi, Moriyama, Saya, Adachi, Yu, Shinoda, Masahiro, Ota, Shinichiro, Morikawa, Miwa, Mineshita, Masamichi, Matsumura, Takayuki, Takahashi, Yoshimasa, Shinkai, Masaharu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.03.2022; MDPI
• Subjects: Age; Amides - therapeutic use; Antibodies; Antibodies, Neutralizing - metabolism; Antibodies, Viral; Antiviral drugs; Body mass index; Clinical trials; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Disease; favipiravir; FDA approval; Gender; Hospitals; Humans; Immunoglobulin G; Infections; Influenza; neutralization breadth index; Neutralization Tests; neutralizing antibody; neutralizing potency index; Nucleoside analogs; Patients; Plasma; Pneumonia; Polymerase chain reaction; Pyrazines - therapeutic use; RNA polymerase; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - metabolism; Spike protein; United States > US; Japan; COVID-19; neutralizing antibody; SARS-CoV-2; neutralization breadth index; neutralizing potency index; favipiravir

The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus...